This compound is primarily utilized in the field of biomedical research, particularly in the study of targeted protein degradation. It functions as a Proteolysis Targeting Chimera (PROTAC) specifically designed to degrade the estrogen-related receptor alpha (ERRα). By facilitating the ubiquitination and subsequent degradation of ERRα, it serves as a valuable tool for investigating the role of ERRα in various biological processes, including metabolism, energy homeostasis, and cancer progression. Its application is significant in developing potential therapeutic strategies for diseases where ERRα plays a critical role, such as certain types of cancers and metabolic disorders. Researchers also use it to explore the mechanisms of PROTAC technology and its efficacy in selectively degrading target proteins.